IL-24 is the key effector of Th9 cell-mediated tumor immunotherapy.
Chen J, Zhang Y, Zhang H, Zhang M, Dong H, Qin T, Gao S, Wang S.
Chen J, et al. Among authors: zhang m, zhang h, zhang y.
iScience. 2023 Aug 3;26(9):107531. doi: 10.1016/j.isci.2023.107531. eCollection 2023 Sep 15.
iScience. 2023.
PMID: 37680459
Free PMC article.